SHARON BRADNI: Open Payments
NPI 1902314933 · FRESNO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,285 in 99 payments from 24 companies in 2025. Trend: 2023 $544 · 2024 $4,295 · 2025 $4,285
Food & beverage: $4,064Education: $221
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 24 | $883 |
| ABBVIE INC. | 20 | $710 |
| UCB, Inc. | 8 | $506 |
| Otsuka America Pharmaceutical, Inc. | 5 | $297 |
| Neurocrine BioSciences, Inc. | 5 | $252 |
| Axsome Therapeutics, Inc. | 5 | $218 |
| SK Life Science, Inc. | 4 | $214 |
| PFIZER INC. | 7 | $200 |
| Amneal Pharmaceuticals LLC | 2 | $148 |
| Novo Nordisk Inc | 1 | $125 |
Products named: AUSTEDO XR, QULIPTA, REXULTI, INGREZZA, Symbravo, Fintepla, Briviact, Nayzilam.
Industry payments across CA — which companies pay providers there.
